These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 20136533)

  • 1. Self-reported side effects in children and adolescents taking risperidone.
    Byrne S; Walter G; Hunt G; Soh N; Cleary M; Duffy P; Crawford G; Krabman P; Concannon P; Malhi G
    Australas Psychiatry; 2010 Feb; 18(1):42-5. PubMed ID: 20136533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
    Aman MG; Gharabawi GM;
    J Clin Psychiatry; 2004 Sep; 65(9):1197-210. PubMed ID: 15367046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups.
    Curran S; Turner D; Musa S; Wattis J
    Int J Geriatr Psychiatry; 2005 Sep; 20(9):842-7. PubMed ID: 16116576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substituting traditional antipsychotics with risperidone for individuals with mental retardation.
    Simon EW; Blubaugh KM; Pippidis M
    Ment Retard; 1996 Dec; 34(6):359-66. PubMed ID: 8990820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living.
    Yoon JS; Kim JM; Lee H; Shin IS; Choi SK
    Hum Psychopharmacol; 2003 Dec; 18(8):627-33. PubMed ID: 14696022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents.
    Swadi HS; Craig BJ; Pirwani NZ; Black VC; Buchan JC; Bobier CM
    Int Clin Psychopharmacol; 2010 Jan; 25(1):1-6. PubMed ID: 19809337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open clinical trial of risperidone monotherapy in young children with autistic disorder.
    Findling RL; Maxwell K; Wiznitzer M
    Psychopharmacol Bull; 1997; 33(1):155-9. PubMed ID: 9133768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risperidone in the ambulatory treatment of behavior disorders in demented patients of Alzheimer's type: a retrospective analysis].
    Sobów TM; Kłoszewska I
    Psychiatr Pol; 2001; 35(6):1033-45. PubMed ID: 11877883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic malignant syndrome with risperidone.
    Gleason PP; Conigliaro RL
    Pharmacotherapy; 1997; 17(3):617-21. PubMed ID: 9165568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reader response to, "Effects of risperidone on aberrant behavior in persons with developmental disabilities: I. A double-blind crossover study using multiple measures".
    Levitas A
    Am J Ment Retard; 2003 May; 108(3):212-4; author reply 214-6. PubMed ID: 12691600
    [No Abstract]   [Full Text] [Related]  

  • 14. Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.
    Tchan MC; Sillence D
    J Intellect Dev Disabil; 2009 Sep; 34(3):275-9. PubMed ID: 19681008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Movement disorders in children with developmental disabilities taking risperidone.
    Demb HB; Nguyen KT
    J Am Acad Child Adolesc Psychiatry; 1999 Jan; 38(1):5-6. PubMed ID: 9893407
    [No Abstract]   [Full Text] [Related]  

  • 16. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior.
    Buitelaar JK
    J Child Adolesc Psychopharmacol; 2000; 10(1):19-26. PubMed ID: 10755578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A crossover study of risperidone in children, adolescents and adults with mental retardation.
    Hellings JA; Zarcone JR; Reese RM; Valdovinos MG; Marquis JG; Fleming KK; Schroeder SR
    J Autism Dev Disord; 2006 Apr; 36(3):401-11. PubMed ID: 16596465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pediatric psychiatry: children and antipsychotic drugs: clinical monitoring by the nurse assures a safe course in children taking antipsychotic drugs].
    Fournier A; Laflamme F
    Perspect Infirm; 2010; 7(5):19-21. PubMed ID: 21744626
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy.
    Vercammen L; Buyse GM; Proost JE; Van Hove JL
    J Inherit Metab Dis; 2003; 26(6):611-2. PubMed ID: 14605508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice.
    Morrison P; Gaskill D; Meehan T; Lunney P; Lawrence G; Collings P
    Aust N Z J Ment Health Nurs; 2000 Dec; 9(4):166-76. PubMed ID: 11887267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.